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Abstract
There is increasing evidence to suggest that splicing decisions are largely made when the nascent RNA is still associated
with chromatin. Here we demonstrate that activity of histone deacetylases (HDACs) influences splice site selection. Using
splicing-sensitive microarrays, we identified ,700 genes whose splicing was altered after HDAC inhibition. We provided
evidence that HDAC inhibition induced histone H4 acetylation and increased RNA Polymerase II (Pol II) processivity along an
alternatively spliced element. In addition, HDAC inhibition reduced co-transcriptional association of the splicing regulator
SRp40 with the target fibronectin exon. We further showed that the depletion of HDAC1 had similar effect on fibronectin
alternative splicing as global HDAC inhibition. Importantly, this effect was reversed upon expression of mouse HDAC1 but
not a catalytically inactive mutant. These results provide a molecular insight into a complex modulation of splicing by
HDACs and chromatin modifications.
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Introduction
Pre-mRNA splicing is an essential step in eukaryotic gene
expression and its regulation vastly increases the coding potential
of our genome. Splicing is catalyzed by the spliceosome which
consists of spliceosomal small ribonucleoproteins (snRNPs) and
additional splicing factors [1]. The critical step in splicing is intron
recognition; this is achieved through the association of the splicing
machinery with pre-mRNA via RNA-RNA and protein-RNA
interactions. Interestingly, there is an increasing body of evidence
suggesting that these interactions are not the only determinants of
the splice-site definition [2].
There are many examples of a close coupling between
transcription and splicing ([3,4] reviewed in [5,6]). Several splicing
factors interact with RNA polymerase II (Pol II), which is
important for their recruitment to pre-mRNA and through the
combination of Pol II processivity and promoter identity, splice-
site selection is influenced ([7,8,9,10] reviewed in [11]). This
regulation involves a co-transcriptional definition of splice-sites,
spliceosome assembly and splicing [12,13]. Indeed, the major
regulators of splicing, snRNPs and SR proteins, are found at the
site of active transcription [14,15,16,17,18], demonstrating that
the splicing machinery assembles while the pre-mRNA is still
associated with the DNA template. Such an observation suggests
that chromatin modification might potentially play a regulatory
role in splicing.
In yeast, the histone acetyltransferase found in the SAGA
complex, Gcn5 is involved in co-transcriptional recruitment of the
U2 snRNP [19]. In higher eukaryotes, the SWI/SNF chromatin
remodeling complex associates with pre-mRNA and regulates
alternative splicing of endogenous genes [20,21] and treatment
with histone deacetylase inhibitor trichostatin A (TSA) affects
minigene alternative splicing [8]. Additionally, splicing factors
interact directly with modified histones, although the significance
of these interactions for splicing regulation remains unclear
[22,23]. Recently, genome-wide nucleosome mapping revealed
that nucleosome localization correlates with exon positioning and
may be involved in exon recognition [24,25,26,27]. The role of
nucleosome packing was supported by finding that siRNA-induced
formation of heterochromatin influenced alternative splicing [28].
H3K36 tri-methylation differs at alternative and consecutive exons
and affects alternative splicing through splicing factor recruitment
[29,30,31,32]. In addition, cell membrane depolarization resulted
in altered RNA polymerase II transcription and chromatin
modifications, correlating with alternative splicing changes [30].
In this study we examined whether enzymes catalyzing histone
deacetylation can modulate alternative splicing of human genes.
Results
HDAC activity regulates alternative splicing
In order to explore the effects of HDAC activity on alternative
splicing we treated cells with the potent HDAC inhibitor, sodium
butyrate (NaB) and monitored splicing changes by exon arrays.
The analysis revealed that the splicing of 683 genes (out of 17,771
human genes included in the analysis) was altered upon HDAC
inhibition (Table S1). Targeted genes are mainly involved in
signaling (transmembrane transporters and receptors), transcrip-
tion regulation, apoptosis, cell cycle and cell organization, all
processes that regulate cell fate and differentiation (Fig. 1a).
Interestingly, one of the target genes was encoding the Tau
protein, which is abundantly expressed in central nervous system
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diseases as frontotemporal dementia with Parkinsonism linked to
chromosome 17 (FTDP-17) [33]. The NaB treatment reduced
expression ofthe splicevariant that isupregulated duringthedisease
(Fig. 1c). Exons with high splicing change ($3 fold) were further
analyzed with respect to their inclusion or exclusion (Fig. 1b). While
we found a partial preference for overall exon inclusion (389
included/294 excluded) there was a strong correlation between
increased gene expression and alternative events with a partial bias
towards exon exclusion in up-regulated genes. Recently, a similar
relationship was observed when a smaller set of genes was analyzed
after UV irradiation [34]. These data suggest that HDAC inhibition
did not only alter transcription but also substantially affected
splicing pattern. To confirm exon-array results 16 target genes were
further analyzed by conventional RT-PCR. Thirteen genes
exhibited alternative splicing changes predicted by exon-arrays.
Splicing pattern of nine of them is shown in Fig. 1c together with
two control exons with no splicing change (Fig. 1d).
Histone H4 acetylation correlates with alternative
splicing
One of the genes most affected by HDAC inhibition was
fibronectin (FN1). Given that fibronectin’s alternative splicing
variants are well described and have been extensively studied
[35,36,37], we decided to use this gene to further characterize the
role of HDACs in alternative splicing. As a model we analyzed
exon 25 (called EDB or EDII) that was influenced by HDAC
inhibition and exon 33 (called EDA or EDI) that did not alter
splicing pattern upon NaB treatment. Moreover, one of the major
advantageous is that proteins regulating splicing of the EDB exon
were identified. It was shown that SR proteins, in particular
SRp40, and PTB are important for EDB inclusion [38,39,40,41].
To test a potential mechanism via HDACs influence alternative
splicing we first analyzed whether HDAC inhibition affected
expression of general splicing proteins (namely snRNP specific
proteins) and splicing regulators (SR proteins or PTB) (Fig. 2a,b).
Using the monoclonal antibody m104 that recognizes a set of
Figure 1. HDAC inhibition induces global changes in alternative splicing. HDAC activity was inhibited by treating cells with sodium butyrate
(NaB) and splicing changes monitored by exon arrays. The splicing pattern of over 680 genes was changed (see Table S1). (A) Gene ontology analysis
was performed with genes from the microarray annotation file as a background, enrichment score is the -log (p-value) of the chi-square test.
Functional groups of over-represented genes with enrichment score .3 are shown. (B) Exons with high change ($3-fold) were analyzed with respect
to their inclusion or exclusion and divided into three groups according to the expression of a gene where the alternative exons are localized. (C)
Several genes identified as top hits by microarray were confirmed by RT-PCR. Alternative exons were skipped after NaB treatment in three genes
(CACNA1G, FN1 –exon 24 and MAPT). In KREMEN1 alternative 59splice site was used and in CAPN5, RFX2, ITGB4, PLTP and CACNA1H alternative exons
were included after HDAC inhibition. A graphic illustration of microarray data representing the same genomic loci as RT-PCR is shown next to the gels
(non-treated cells - grey line; NaB treatment - black line). Exon array data show expression of individual alternative exons and neighboring
constitutive exons. Relative decrease of the signal from alternative exon probes indicates alternative exon skipping, e.g. CACNA1G alternative exon
signal from control cells (grey line) is higher compared to the surrounding constitutive exons than signal from NaB treated cells (black line). Although
CACNA1G gene expression is elevated in NaB treated cells, the expression of alternative exon decreased, because this exon is preferentially skipped.
(D) Two control exons that did not change splicing pattern upon NaB treatment.
doi:10.1371/journal.pone.0016727.g001
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HDAC inhibition did not significantly alter the level of
phosphorylated SR proteins (Fig. 2a). In addition, we used a
HeLa cell line stably expressing SRp40-GFP from a bacterial
artificial chromosome (BAC) that preserved endogenous SRp40
regulatory elements [43]. No change in SRp40-GFP expression
was observed following the NaB treatment (Fig. 2b). Moreover, we
did not observe any difference in expression of PTB, Pol II or core
spliceosomal components hSnu114, hPrp4, U5-40K and SmB. It
was shown recently that several splicing regulators including
SRp40 are acetylated [44]. Therefore, we probed acetylation level
of SRp40 before and after HDAC inhibition but did not find any
significant changes in SRp40 acetylation status (Fig. 2c).
To further test whether the HDAC inhibition caused overex-
pression of other splicing factors that may potentially regulate
fibronectin alternative splicing, cellular protein synthesis was
inhibited in conjunction with HDAC activity. The inhibition of
protein synthesis itself did not have any significant effect on EDB
splicing. Further, we did not observe any differences in the splicing
of the EDB exon whether cells were treated in combination with
the ribosomal and HDAC inhibitors or HDAC inhibitor alone
(Fig. 2d). These data indicated that NaB treatment did not
influence splicing via altered expression or modification of
regulatory proteins.
Next, we performed a detailed analysis of chromatin marks
along the FN1 gene including the EDA exon where we did not
detect any change in alternative splicing after NaB treatment. First
we determined the level of acetylated histone H3 and H4.
Acetylation of histone H3 was maximal at the promoter and
dropped in the body of the gene. HDAC inhibition resulted in
decreased H3 acetylation at the promoter (likely reflecting
clearance of the promoter; see Fig. 3h) and partial increase within
the gene (Fig. 3a). In non-treated cells general H4 acetylation was
highest at the promoter. After HDAC inhibition, general H4
acetylation was more uniform and high all over the gene (Fig. 3b).
Interestingly, the increase of H4 acetylation was significantly
higher at the EDB exon than at the EDA exon, whose splicing did
not respond to HDAC inhibition. Notably, different lysine residues
within histone H4 contributed differently to the general H4
acetylation with highest increase at the lysines 8 and 12 (Fig. 3c–f).
Next, we analyzed the level of lysine 36 tri-methylation at histone
H3 as this modification was recently described as a marker of exon
associated chromatin that influenced alternative splicing
[30,31,32]. H3K36 tri-methylation increased partially within the
gene body, including the alternative exon (Fig. 3g). At the same
time no change was found in general nucleosome occupancy
within the body of the gene (Fig. 3h). Together, these data show
that HDAC inhibition has a global effect on chromatin
modifications within the FN1.
As the maximal changes observed were in the acetylation of
histone H4, we tested whether this modification correlated with
alternative splicing. First, we measured the dynamics of H4
acetylation after HDAC inhibition in HeLa cells (Fig. 4a). Histone
acetylation rapidly increased after 3 h of treatment and reached
maximal levels within 6–9 h. However, little splicing effects were
observed within this time period (Fig. 4b and data not shown).
This discrepancy could be caused by mRNA being synthesized
and spliced before HDAC inhibition. Thus, the presence of this
mRNA might delay the detection of any splicing changes. To
reduce the effect of mRNA spliced before HDAC inhibition, cells
were incubated for 6 h with DRB, a reversible inhibitor of Pol II.
Following this incubation, the Pol II inhibitor was removed and
the cells were treated with NaB for an additional 6 h and EDB
inclusion analyzed (Fig. 4b). The subsequent results show that as
soon as 6 h post HDAC inhibition, the splicing of de novo
synthesized pre-mRNA was altered. To further test the correlation
between histone H4 acetylation and FN1 splicing, we analyzed H4
acetylation in a retinoblastoma derived cell line Y79 that almost
exclusively included the alternative exon (Fig. 4c). Using three
different loci of the fibronectin gene, we show that general histone
H4 acetylation is reduced in Y79 cells with respect to HeLa cells
(Fig. 4d).
Pol II processivity changes after HDAC inhibition
Our data suggest a link between alternative splicing and H4
acetylation. It was previously shown that H4 acetylation was
associated with Pol II processivity [45]. Moreover, there have been
several observations that suggested a close relationship between
Pol II dynamics and alternative splicing [7,46]. Based on these
observations we decided to analyze whether HDAC inhibition
affects Pol II processivity. We probed Pol II processivity at several
FN1 gene loci by measuring the ratio between two pre-mRNA
fragments as described previously [30] (Fig. 5a). Our results
Figure 2. HDAC inhibition does not alter phosphorylation,
acetylation or expression of SRp40. (A) HeLa cells or (B) HeLa cells
stably expressing SRp40-GFP from BAC were treated for 15 h with NaB
and levels of SR proteins were analyzed by Western blotting with the
m104 antibody recognizing an SR protein phospho-epitope (A) or anti-
GFP antibody (B). In addition, HDAC inhibition did not alter expression
of several splicing proteins or RNA polymerase II. (C) SRp40-GFP was
immunoprecipitated from SRp40-GFP stable cell line before and after
HDAC inhibition and acetylation assayed by anti-acetyl lysine antibody.
No significant change was observed after six hours NaB treatment.
Representative Western blot and the average of three independent
experiments is shown. (D) Inhibition of protein synthesis does not affect
alternative splicing of the EDB exon in the FN1 gene. Cells were treated
for 9 h with cycloheximide (CHX), sodium butyrate (NaB) or both and
EDB splicing assayed by RT-PCR and RT-qPCR (graph). Inhibition of
HDAC by NaB had a similar effect on EDB skipping after CHX treatment.
A representative RT-PCR (gel) and the average of three independent
quantitative RT-PCR experiments (graph) are shown including SEM,
** indicates p#0.01 of the t-test with respect to non-treated cells.
doi:10.1371/journal.pone.0016727.g002
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EDB exon that was excluded but only small change at the alternative
EDA exon that did not change splicing after HDAC inhibition.
Next, we determined the distribution of total Pol II as well as
Pol II phophorylated at the C-terminal domain along the
fibronectin gene after HDAC inhibition (Fig. 5b–d). Consistent
with elevated levels of fibronectin mRNA (,5-fold, see Table S1),
we observed an increased occupancy of total Pol II and Pol II
phosphorylated at Ser-5 at the promoter indicating a higher
frequency of transcription initiation (Fig. 5b,c). Surprisingly, we
found lower Ser-2 phosphorylation along the gene upon HDAC
inhibition with EDB exon as the only exception, which likely
reflects accumulation of total Pol II at the EDB exon (Fig. 5d). In
addition, we observed accumulation of total Pol II at the EDB
exon and the intronic sequence downstream of the EDB exon.
Together with measurements of Pol II processivity these data
indicated that HDAC inhibition resulted in increased Pol II
processivity at upstream and downstream introns and slow down
at the EDB exon. HDAC inhibition thus had a complex effect on
Pol II distribution, phosphorylation and processivity along the
fibronectin gene.
HDAC inhibition decreases the association of SRp40 with
the FN1 gene
The EDB exon is regulated by several cis-regulatory elements. A
couple SRp40 binding sites were found within the EDB exon and
the downstream intron, while PTB sites were identified upstream
of the alternative exon. It was reported that EDB exon is
recognized and spliced co-transcriptionaly [12] and that SR
proteins directly associate with the nascent RNA at the
transcription site [17]. Therefore, we decided to test whether
HDAC inhibition influenced the interaction of SRp40 or PTB
with the nascent RNA at the transcription site. To detect SRp40 at
the transcription unit, we used a recently developed system that
utilizes GFP tagged SR proteins and chromatin immunoprecip-
itation (ChIP) [17]. This report showed that GFP tagged SR
proteins are expressed at the same or at lower levels than the
Figure 4. H4 acetylation correlates with EDB exon skipping. (A) The dynamics of histone H4 acetylation was assayed by Western blotting at
different times after NaB treatment. A representative blot and the average of three experiments are shown including SEM. (B) EDB splicing was
assayed six hours after HDAC inhibition. To reduce the possible effects of mRNA synthesis before HDAC inhibition, cells were treated with the Pol II
inhibitor, DRB before the addition of HDAC inhibitor (NaB). The same amount of total RNA was used in each reaction. Following Pol II inhibition
changes in EDB splicing were detected six hours post NaB treatment. A representative RT-PCR (gel) and the average of three independent
quantitative RT-PCR experiments (graph) are shown including SEM. (C) EDB inclusion was analyzed in two different cell lines (Hela and Y79) using RT-
PCR. (D) Histone H4 acetylation in HeLa and Y79 was assayed by chromatin immunoprecipitation at the EDB exon and the surrounding regions (see
graphical representation of the gene loci below the graph). The average of three experiments is shown including SEM, ** indicates p#0.01 and
*p #0.05 of the t-test.
doi:10.1371/journal.pone.0016727.g004
Figure 3. HDAC inhibition induces histone acetylation along the FN1 gene. Chromatin immunoprecipitations were performed 6 h after
HDAC inhibition with NaB using antibodies against (A) acetylated H3, (B) acetylated H4, (C) acetylated H4 lysine 5, (D) acetylated H4 lysine 8, (E)
acetylated H4 lysine 12, and (F) acetylated H4 lysine 16. In addition, (G) tri-methylated lysine 36 histone H3, and (H) total H3 were probed. Probes
detecting gene loci around alternative EDB exon are shaded. The average of at least three experiments is shown including SEM, ** indicates p#0.01
and * p#0.05 of the t-test.
doi:10.1371/journal.pone.0016727.g003
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indistinguishable from its endogenous counterpart. Our results
revealed that SRp40 association with the FN1 gene decreased upon
HDAC inhibition, with the most significant decrease at the alternative
EDB exon (Fig. 6a). The observed decrease was not a result of overall
reduction of SRp40 protein level because HDAC inhibition did not
alter SRp40 expression (Fig. 2b). In contrast, we did not detect any
significant changes in association of PTB or general splicing Sm
proteins over the alternative EDB exon indicating that changes in
SRp40 interaction were not due to general changes in gene accessibility
(Fig. 6b,c). These data indicated that HDAC activity influenced co-
transcriptional association of SRp40 with the EDB exon.
HDAC1 activity modulates fibronectin alternative splicing
To test whether the observed effects on alternative splicing were
specific for NaB or whether it was a general property of HDAC
inhibitors we reduced HDAC activity using three different
inhibitors - TSA, valproic acid (VPA) and NaB and determined
their effect on splicing of the fibronectin exon EDB. TSA is a pan-
HDAC isoform inhibitor that in vitro displays nM potency against
HDAC classes I (HDAC 1, 2, 3 and 8) and II (HDAC 4, 5, 6, 7, 9
and 10) with the exception of HDAC8, which is in the low mM
range [47]. VPA is an established drug in the long-term therapy of
epilepsy. It is a class I selective HDAC inhibitor, which in vitro
inhibits HDAC 1, 2, 3 and 8 in the mM range [48]. Finally,
Figure 5. Pol II processivity correlates with exon skipping. (A) Pol II processivity was determined as a ratio of two pre-mRNA sequences (B:A)
along several regions of the FN1 gene. The abundance of given pre-mRNA locus was determined by quantitative PCR. The increased ratio after NaB
treatment indicates higher Pol II processivity over the assayed region. Pol II exhibited high processivity increased significantly upstream and
downstream of the EDB exon but not over consecutively spliced intron or alternative EDA exon that was not affected by NaB treatment. The average
of three experiments is shown including SEM, * indicates p#0.05 the t-test. (B-D) HDAC inhibition affects Pol II distribution. HDAC activity was
inhibited by NaB for six hours and distribution of (B) total Pol II, (C) Pol II phosphorylated at the C-terminal domain Ser-5, and (D) Pol II
phosphorylated at the C-terminal domain Ser-2 was assayed along the gene by chromatin immunoprecipitation. Probes detecting gene loci around
alternative EDB exon are shaded. The tested gene loci are the same as in fig. 3. The average of three experiments is shown including SEM, ** indicates
p#0.01 and * p#0.05 of the t-test.
doi:10.1371/journal.pone.0016727.g005
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inhibits class I HDACs, but also HDAC 10 [47]. Following the
treatment of cells with each HDAC inhibitor we observed the
exclusion of the EDB exon in all cases, albeit with differing
efficiencies, which might reflect the fact that targets of these
inhibitors were not fully overlapping (Fig. 7a). The effect on
alternative splicing was detectable after 12 h of HDAC inhibition
and sustained for an additional 12 h. The smallest exclusion was
observed after VPA treatment and Western blot analysis of H4
acetylation revealed that VPA had the smallest effect on H4
acetylation (data not shown). These results correlated with
previous finding that different inhibitors regulated acetylation of
core histones with different efficiencies [44].
To further investigate the role of HDACs in alternative splicing,
two highly expressed enzymes from the HDAC class I family,
HDAC 1 and 2, were knocked-down by RNAi (Fig. S1). Similar to
HDAC inhibition, depletion of HDAC1 but not HDAC2 had a
strong effect on fibronectin splicing, resulting in EDB skipping
(Fig. 7b). To demonstrate the splicing effect of the RNAi treatment
was specific to HDAC1, we used RNAi-resistant mouse HDAC1,
which reverted the EDB splicing pattern (Fig. 7c and Fig. S1a).
The requirement for HDAC1 activity was further supported by
expression of HDAC1 mutant carrying an inactivating mutation
within the active site [49], which was unable to rescue the splicing
phenotype after RNAi treatment. These results together with
HDAC inhibition data demonstrate that the enzymatic activity of
HDAC1 is important for the regulation of fibronectin alternative
splicing.
Discussion
There is an increasing amount of evidence to show that
chromatin modifications play a vital role in pre-mRNA splicing.
However, little is known about the mechanism and factors
involved in this coupling. In this study, we show that alternative
splicing of a hundreds of genes is regulated by HDAC activity.
Recently published in vitro data indicate that several HDAC
inhibitors work by stalling the splicing reaction, suggesting that
protein acetylation might have a role in regulating splicing activity.
However, Kuhn and his co-workers did not identify a potential
protein target, leaving the mechanism of HDAC inhibitor action
on splicing open [50]. In our study, we did not observe any
Figure 6. HDAC inhibition reduces SRp40 association with the EDB exon. (A) SRp40-GFP stably expressed from a BAC cell line was
immunoprecipitated using an anti-GFP antibody. SRp40 interaction with the FN1 gene was measured in cells treated for 6 h with NaB and in control
cells. No changes in distribution of another splicing regulator PTB (B) or general splicing factors Sm proteins (C) were detected. Probes detecting gene
loci around alternative EDB exon are shaded. The average of 3-5 experiments is shown, including SEM, ** indicates p#0.01 and * p#0.05 of the t-test.
doi:10.1371/journal.pone.0016727.g006
Figure 7. HDAC1 depletion affects EDB splicing. (A) Cells were
treated with three different HDAC inhibitors (trichostatin A - TSA,
valproic acid - VPA and sodium butyrate - NaB) for 12 h and 24 h. Their
effect on fibronectin alternative EDB exon splicing was analyzed by RT-
PCR (gel) or quantitative RT-PCR (graph). DMSO and non-treated cells
served as negative controls. (B) HDAC1 and HDAC2 were down-
regulated using siRNA and the resulting EDB splicing assayed. Depletion
of HDAC1 but not HDAC2 resulted in EDB exon skipping. For knock-
down efficiency see Fig. S1. (C) Endogenous HDAC1 was knocked-down
by siRNA. The EDB skipping phenotype was rescued by expressing the
mouse HDAC1 homologue (mHDAC1) but not an inactive mouse
HDAC1 mutant (D174H). NC - negative control siRNA, control plasmid -
GFP transfected cells. Expression of endogenous human (hHDAC1) and
ectopically expressed mouse HDAC1 (mHDAC1) is shown below the
graph. Graphs represent the average of three independent experiments
measured by quantitative RT-PCR including SEM, ** indicates p#0.01
and * p#0.05 of the t-test.
doi:10.1371/journal.pone.0016727.g007
HDACs Regulate Alternative Splicing
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e16727decrease in global mRNA production indicating that general
splicing was not inhibited after HDAC inhibition with NaB. Thus,
it remains to be clarified whether the observed in vitro effects of
HDAC inhibitors apply to in vivo as well. Interestingly, about half
of the proteins found in the spliceosome are acetylated but the
functional role of these acetylations in splicing is yet to be
established [44]. In addition, Mathias Mann and his colleagues
tested two different HDAC inhibitors (SAHA targeting both
HDAC classes I and II and MS-275 targeting class I) and found
surprisingly low overlap of proteins with enhanced acetylation (43
out of 1750 proteins). Interestingly, histones were among the
common targets and their acetylation increased after treatment
with both drugs [44]. Here, we showed that at least two different
inhibitors had the same effect on fibronectin splicing suggesting
that both act via increased acetylation of histones as shared targets
of different HDAC inhibitors. Moreover, we analyzed acetylation
of the splicing regulator SRp40 but did not detect any changes
upon HDAC inhibition. Despite that we cannot absolutely rule out
the possibility that HDACs affect splicing via deacetylation of
splicing proteins.
Recently it was shown in yeast that histone acetyltransferase
Gcn5 affects co-transcriptional recruitment of U2 snRNPs [19].
The authors proposed that H3 acetylation at the promoter is
responsible for the association of splicing factors with Pol II,
resulting in their recruitment to the transcription unit. Our results
with HDAC inhibitors suggest that histone acetylation can play a
more direct role within the gene body. Histone acetylation around
alternatively spliced elements affects splicing through the alteration
of Pol II processivity that consequently modulates co-transcrip-
tional association of splicing regulators with the nascent RNA.
The coupling betweenthe elongation rate and alternative splicing
was previously indicated by several studies. It was shown that the
mutation in Pol II affecting the speed of synthesis, introduction of a
pause site into the DNA template or depletion of transcription
elongation factors influence alternative splicing outcome of
transiently expressed reporter genes [7,11,28,30,46,51,52]. How-
ever, a direct molecular link between transcription dynamics and
alternative splicing has not been described. Karla Neugebauer and
her colleagues showed that reduction of RNA synthesis rate by
camptothecin increases association of general splicing factors with
the transcription unit indicating a kinetic coupling between RNA
synthesis and interaction of splicing factors with the nascent RNA
[16]. Here we describe that increase of Pol II dynamics in the
vicinity of the alternative EDB exon correlates with reduced co-
transcriptional recruitment of SRp40 supporting the model of
kinetic coupling between transcription and splicing. It was shown
that co-transcriptional association of SR proteins with the
transcription unit is RNA dependent and determined by the RNA
recognition domain [17]. Here we show that SR protein interaction
with the transcription unit also depends on HDAC activity. In
addition, SRp40 distribution does not correlate with Pol II
occupancy, indicating that SRp40 does not interact primarily with
Pol II.
More than 20 years ago it was hypothesized that splice-site
selection is accomplished within a short window after transcription
when RNA is naked and splicing factors can interact with target
sequences [53]. Since then, co-transcriptional recognition of
splice-sites was further supported by the study of Roberts et al.
[52] and the significance of co-transcriptional splice-site recogni-
tion was recently demonstrated using the EDB exon that is
recognized and spliced co-transcriptionally [12,13]. Here we
propose that co-transcriptional recruitment of splicing factor is
modulated by histone modifications and Pol II processivity, which
provides a link between chromatin modifications, transcription
and splicing. Because NaB treatment leads to exclusion as well as
inclusion of alternative exons we speculate that HDAC inhibition
reduces the interaction of splicing enhancers (in the case of exon
exclusion) or silencers (in the case of exon inclusion).
Our data also provide an example of how global changes in
chromatin structure can result in local changes within specific
genes. Global analysis of alternative splicing further revealed that
many genes whose alternative splicing is regulated by HDACs
belong to families of proteins that are involved in signaling and cell
organization; processes that are tightly connected with cell
differentiation. The dynamic interplay between chromatin struc-
ture, transcription and splicing might explain why some genes are
alternatively spliced in different cell types that contain the same or
a similar set of splicing regulators and as such might represent an
efficient method for global splicing regulation during development
and cell differentiation. In addition, many genes affected by
HDAC inhibitor are involved in regulation of membrane
potential, a process linked to signal transduction in neurons.
Thus, HDAC inhibitors (e.g. VPA) used in epilepsy treatment
might act via modulation of splicing pattern in patient neurons.
For example, misbalanced splicing of Tau protein is a primary
cause of frontotemporal dementias. Interestingly, Tau gene is on
the list of genes whose splicing is modulated by HDAC inhibition.
HDAC inhibitors thus might serve as a drug that acts via alteration
of splicing pattern, which can increase their therapeutic potential.
Materials and Methods
Cell culture and treatments
HeLa and HeLa-GFP-SRp40 cells were cultured in DMEM
supplemented with 10% fetal calf serum, penicillin and strepto-
mycin (Invitrogen) and treated with 50 mM DRB (5,6-Dichlor-
obenzimidazole 1-b-D-ribofuranoside), 5 mM sodium butyrate,
5 mM valproic acid, 330 nM trichostatin A (all from Sigma) or
cycloheximide (50 mg/ml, Calbiochem). Y79 human retinoblasto-
ma cells (ATCC HTB-18, a kind gift of Martina Zikova, IMG
ASCR) were cultured in RPMI with 10% fetal calf serum,
penicillin and streptomycin. HeLa-GFP-SRp40 cell line was a gift
from Ina Poser and Tony Hyman from (Max Planck Institute of
Molecular Cell Biology and Genetics, Germany).
Antibodies
The anti-RNA polymerase II H5 monoclonal antibody
(recognizing phosphoserine 2) and H14 antibody (recognizing
phosphoserine 5) were purchased from Covance, polyclonal
antibodies against acetylated lysine 16 histone H4, Pol II (clone
H-224) and mouse anti-GFP antibody (used for Western blotting)
were from Santa Cruz. Monoclonal antibodies specific for
HDAC1, polyclonal for acetyl-histone H4, acetyl-histone H3,
H4K5ac H4K8ac and H4K12ac were all purchased from Upstate.
Anti-H3, anti-H3K36me3 and 8WG16 anti-RNA polymerase II
antibody (used for chromatin immunoprecipitations), anti-
HDAC2 and anti-PTB antibodies were purchased from Abcam.
hSnu114, hPrp4 and U5-40K antiserum was a gift from R.
Lu ¨hrmann (Max Planck Institute of Biophysical Chemistry,
Go ¨ttingen, Germany), monoclonal m104 antibody recognizing
phosphorylated SR proteins was a gift from K. Neugebauer (Max
Planck Institute of Molecular Cell Biology and Genetics,
Germany), anti-tubulin antibody was kindly provided by Pavel
Draber (Institute of Molecular Genetics ASCR, Prague, Czech
Republic), goat anti-GFP antibody used for ChIP was received
from David Drechsel (Max Planck Institute of Molecular Cell
Biology and Genetics, Germany) and the monoclonal anti-PTB
antibody (BB7, used for chromatin immunoprecipitations) was
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Los Angeles, USA). The anti-Sm antibody Y12 was produced
from a hybridoma cell line (a gift of Karla Neugebauer, Max
Planck Institute for Molecular Cell Biology, Dresden, Germany;
[54]) in the antibody facility at the Institute of Molecular Genetics
ASCR. The polyclonal pan anti-acetyl lysine antibody was
obtained from Immunechem. Nonspecific mouse IgG and anti-
mouse IgM were both purchased from Sigma.
Plasmids and siRNA transfection
Mouse HDAC1 cDNA (gift form Konstantinos Anastassiadis,
TUD, Dresden, Germany) was subcloned into EGFP-N1 with
SalI/NotI. The D174H mutation was introduced by PCR site-
directed mutagenesis as described previously [55]. List of primers
used in this study is listed in List S1. Plasmids were transfected
with FuGENE HD (Roche Applied Science) according to
manufacture’s protocol. Preannealed siRNA duplexes were
obtained from Ambion: HDAC1 59-GGGAUACUUUUAUG-
CAACCtt-39; HDAC2 59-GCCACUGCCGAAGAAAUGAtt-39;
The negative control 1 siRNA from Ambion was used as a
negative control. Oligofectamine (Invitrogen) was used for siRNA
transfection according to the manufacture’s protocol. Cells were
incubated for 48 h (78 h for rescue experiments) before further
treatment.
RNA isolation and RT PCR
Total RNA was purified with TRIzol (Invitrogen), reverse
transcribed using SuperScript III (Invitrogen) and cDNA amplified
by Taq polymerase (MBI Fermentas). Primers used for RT-PCR
and qPCR are listed in List S1.
Quantitative real-time PCR
The ratio of mRNA with EDB exon skipped/included was
calculated from relative Ct values of primers 41196 (FN1 exon 24)
and 42658 (FN1 exon 25, EDB) according to Rtreatment=
2
(CtEDB – CtEDBupstream) and normalized to control cells (R
=R treated/Rcontrol). RNA polymerase II processivity was calculat-
ed from relative Ct values of primer pairs A (upstream) and B
(downstream) according to pre-mRNA ratiodistal/proximal=
2
(CtA – CtB).
Exon arrays
HeLa cells were treated with 5 mM NaB for 15 h and their
RNA was isolated with TRIzol. For each sample, 1 mg of total
RNA was processed, amplified, and labeled according to the
Affymetrix GeneChip Whole Transcript (WT) Sense Target
Labeling Assay (P/N 701880 Rev. 5). This protocol resulted in
biotinylated sense strand cDNA samples, which were subsequently
hybridized to GeneChip Human Exon 1.0 ST Array (Affymetrix,
Inc., U.S.). Washing, staining, and scanning of the arrays was done
according to the Affymetrix GeneChip Expression Wash, Stain,
and Scan User Manual (P/N 702731) protocol. The data were
analysed with the Partek Genomics Suite 6.4 software (Partek
Incorporated, U.S.) using the RMA (Robust Multi-Array)
algorithm. Only probesets that were present in the ‘core’ meta-
probe list (17 800 RefSeq genes and full-length GenBank mRNAs)
were used to identify alternative splicing events with Alt-splice
ANOVA. A list of genes with alternative splicing was generated by
using alternative splicing p-values corresponding to the 0.005 FDR
criterion as a cutoff. To identify differentially expressed genes a p-
value of 0.05 FDR was used as a cutoff.
C h a n g e si ne x o ne x p r e s s i o nw e r en o r m a l i z e dt ot h ec h a n g e si ng e n e
expression (NaBexon expression/NTexon expression)/(NaBgene expression/
NTgene expression)a n da l le x o n sw i t hv a l u e s$3w e r ec o n s i d e r e da s
included, exons #1/3 as excluded. All data are MIAME compliant
and that the raw data has been deposited in a MIAME compliant
database (GEO, the accession numbers is GSE17397) available at the
Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/
geo/info/linking.html).
ChIP assays
Y79 or Hela cells (treated with 5 mM NaB for 6 h) were washed
with PBS, crosslinked with 1% formaldehyde/PBS for 15 min at
room temperature and the reaction was stopped by the addition of
glycine (final conc. 125 mM). Cells were scraped into RIPA buffer
(150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS,
50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 0.5 mM PMSF,
complete protease inhibitor cocktail (Calbiochem), 50 mM NaF
and 0.2 mM sodium orthovanadate) and sonicated to generate
,500 nt chromatin fragments. The same total amount of protein
(1 mg or 0.3 mg for histone H3) was used for immunoprecipita-
tion. Immunoprecipitation with the appropriate antibodies (20 mg
anti-P-ser 2 and anti-P-ser 5 RNA Pol II, 5 mg anti-RNA pol II,
12 mg goat anti-GFP, 5 ml anti-PTB, 500 ml Y12 cell supernatant
and 3 mg anti-H3 per reaction) was performed at 4uC overnight.
Subsequently, the beads were rinsed twice with RIPA, four times
with 100 mM Tris-HCl, pH 8.5, 500 mM LiCL, 1% Nonidet P-
40, 1% deoxycholic acid, twice again with RIPA and twice with
TE. Protein-DNA complexes were eluted with 1% SDS for 10
minutes at 65uC, decrosslinked in the presence of 200 mM NaCl
for 5 h at 65uC and treated with 20 mg proteinase K for 30 min at
45uC. DNA was phenol/chloroform extracted, precipitated and
amplified by quantitative real-time PCR on a LightCycler 480
System (Roche Applied Science). Data sets were normalized to
ChIP input values, and the relative proportions of gene fragments
obtained from ChIP with a nonspecific antibody were subtracted
from the values obtained from templates derived from ChIP with
the specific antibody: 2
(Ct(input) – Ct(spec)) -2
(Ct(input) – Ct(unspec)).T o
measure the level of phosphorylated RNA pol II the signal
obtained for gene regions was further normalized to the value
obtained in non-treated cells with the primer pair FN1 65438. To
compare the level of acetylated histone H4 on FN1 in HeLa and
Y79 cells the signal obtained for FN1 was normalized to the primer
pair amplifying an intergenic region on chromosome 10 where no
annotated genes could be found [16].
Native ChIP assays
Hela cells (treated with 5 mM NaB for 6 h) were scraped into
PBS and resuspended in 0.3 M sucrose, 60 mM KCl, 15 mM
NaCl, 5 mM MgCl2, 0.1 mM EGTA, 0,2% NP-40, 15 mM Tris-
HCl, pH 7.7, 0.5 mM DTT, complete protease inhibitor cocktail
(Calbiochem) and 5 mM NaB. Nuclei were released by passage
through a 22 G needle and loaded on a sucrose gradient (1.2 M
sucrose, 60 mM KCl, 15 mM NaCl, 5 mM MgCl2, 0.1 mM
EGTA, 15 mM Tris-HCl, pH 7.7, 0.5 mM DTT, protease
inhibitors and 5 mM NaB) and centrifuged for 20 min at
2000 g, 4uC. Pellets were resuspended in Mnase digestion buffer
(0.32 M sucrose, 1 mM CaCl2, 4 mM MgCl2, 15 mM Tris-HCl
pH 7.7 and protease inhibitors) and digestion performed for 6 min
at 37uC (1U Mnase/30 mg chromatin). Reactions were stopped by
EDTA (final concentration 10 mM) and centrifuged. The
supernatant was taken and the pellet resuspended in 0.2 mM
EDTA, 1 mM Tris/HCl, pH 7.7, incubated for 1 h at 4uC,
centrifuged again and both supernatants mixed. ,100 mgo f
chromatin was diluted in nChIP buffer (50 mM NaCl, 5 mM
EDTA, 50 mM Tris/HCl, pH 7.7) and incubated overnight at
4uC with appropriate antibody (10 mg anti-acetyl H3, 6 mg anti-
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anti-acetyl H4, 6 ml anti-H4K12ac and 5 ml anti-H4K5ac and
anti-H4K8ac). The beads were washed once with nChIP buffer,
then twice in the same buffer with increasing salt concentration
(75 mM NaCl, 125 mM NaCl, 175 mM NaCl). Complexes were
eluted with 1% SDS for 15 min at room temperature, treated with
20 mg proteinase K for 30 minutes at 45uC and DNA was
recovered with the QIAGEN PCR Purification Kit, quantified by
qPCR and signal compared to the input and non-specific
antibody: 2
(Ct(input) – Ct(spec)) -2
(Ct(input) – Ct(unspec)).
Western blotting and immunoprecipitation
Western blotting and immunoprecipitation was performed as
described previously [55]. Protein extraction from TRIzol after
RNA isolation was done according to manufacturer’s protocol.
Supporting Information
Figure S1 HDAC1 activity regulates fibronectin alternative
splicing. (A) Before cells were transfected with wild type mouse
HDAC1 or a control plasmid, endogenous HDAC1 was knocked-
down by siRNA. Subsequently, EDB splicing was analyzed by
RT-PCR. Expression of HDAC1 after siRNA treatment was
assayed by Western blotting. The anti-HDAC1 antibody cross-
reacted with mouse HDAC1, which resulted in an increased signal
in the last line. Snu114 served as a loading control. (B) Reduction
of HDAC2 expression after siRNA treatment. Total RNA and
proteins were isolated from cells treated with HDAC2 siRNA,
negative control siRNA or untreated. The relative amount of
HDAC2 mRNA was assayed by RT-qPCR and protein by
Western blotting.
(EPS)
List S1 Supplementary primer list.
(DOC)
Table S1 Alternative spliced genes decreased expression.
(XLS)
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